diabetic macular edema
Conditions
Interventions
Intravitreous injection of ranibizumab Patients receive 3 initial consecutive monthly injections of ranibizumab. Additional injections are performed as needed.
Combination therapy of intravitreous
Sponsors
Jichi Medica University, Saitama Medical Center
Miyacho Ophthalmic Clinic, Shinkoukai medical corporation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Best corrected-visual acuity measured with a Landolt chart is 0.7 or less than 0.7. HbA1c is less than 10%. Over 3 months must pass since glycemic control begins.
Exclusion criteria
Exclusion criteria: Patients who receive occular surgical treatments within 3 months Patients who receive other macular diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| best-corrected visual acuity (before treatment, 3 months later, 6 months later, 12 months later) total number of injections (for 12 months) change in central retinal subfield thickness (3 months later, 6 months later, 12 months later) | — |
Secondary
| Measure | Time frame |
|---|---|
| fluorescein angiography (before treatment, 3 months later, 6 months later, 12 months later) | — |
Countries
Japan
Contacts
Public ContactAKIRA YANAI
Jichi Medical University, Saitama Medical Center General Affairs Division
Outcome results
None listed